Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2075 of 2529 entries
View as:

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Phase: N/A Priority: Normal
NCT ID: NCT02515331 Org: User:
Start: 11/04/15 End: 08/17/17 Due: 08/17/18

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT04589663 Org: User:
Start: 06/07/21 End: 04/11/22 Due: 04/11/23

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Phase: N/A Priority: Normal
NCT ID: NCT02573467 Org: User:
Start: 11/02/15 End: 02/13/17 Due: 02/13/18

Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00438360 Org: User:
Start: 05/31/06 End: 11/30/07 Due: 11/30/08

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04741789 Org: User:
Start: - End: - Due: -

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT05170724 Org: User:
Start: - End: - Due: -

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT04079231 Org: User:
Start: 02/01/21 End: 01/31/23 Due: 01/31/24

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Phase: N/A Priority: Normal
NCT ID: NCT01030952 Org: User:
Start: 12/31/09 End: 02/28/11 Due: 02/28/12

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Phase: N/A Priority: Normal
NCT ID: NCT02712983 Org: User:
Start: 02/08/17 End: 03/20/19 Due: 03/20/20

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00964665 Org: User:
Start: 07/31/09 End: - Due: -

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03440736 Org: User:
Start: 02/28/18 End: 06/03/22 Due: 06/03/23

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00880269 Org: User:
Start: 08/31/09 End: 02/29/12 Due: 02/28/13

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Phase: N/A Priority: Normal
NCT ID: NCT03867201 Org: User:
Start: 08/26/19 End: 04/30/24 Due: 04/30/25

MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04837703 Org: User:
Start: - End: - Due: -

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01811485 Org: User:
Start: 05/31/13 End: 02/28/14 Due: 02/28/15

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Phase: N/A Priority: Normal
NCT ID: NCT05269771 Org: User:
Start: - End: - Due: -

To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT01846299 Org: User:
Start: 10/31/13 End: 09/30/15 Due: 09/30/16

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Phase: N/A Priority: Normal
NCT ID: NCT04085653 Org: User:
Start: - End: - Due: -

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT06486779 Org: User:
Start: 12/10/24 End: 12/30/28 Due: 12/30/29

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Phase: N/A Priority: Normal
NCT ID: NCT02482428 Org: User:
Start: 05/12/15 End: 05/31/16 Due: 05/31/17

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00757757 Org: User:
Start: 09/30/08 End: 08/31/09 Due: 08/31/10

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT03138811 Org: User:
Start: 12/18/17 End: 07/16/19 Due: 07/16/20

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03096847 Org: User:
Start: 10/24/16 End: 02/06/20 Due: 02/06/21

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00663832 Org: User:
Start: 02/29/08 End: - Due: -

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Phase: N/A Priority: Normal
NCT ID: NCT01705236 Org: User:
Start: 08/20/12 End: 02/18/19 Due: 02/18/20